Project Grant R01HL179812
Award Date
5/1/25
Completion Date
3/31/30
Dollars Obligated
$683K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
This $605,275 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to delineate the developmental mechanisms controlling left-right patterning of the interventricular septum and how perturbations lead to ventricular septal defects. The grant funds work to test hypotheses that the secreted guidance cues netrin-1 (NTN1) and slit-2 (SLIT2) regulate boundary positioning and integrity, respectively, to segregate left...
The Research Institute at Nationwide Children's Hospital (RINCH) received a $711,039 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The project, titled "Role of Cardiac m6A Methyltransferases", aims to investigate the functions of the m6A methyltransferases METTL3 and METTL14 in embryonic mouse myocardium and determine if their dysregulation contributes to the pathogenesis of fetal dilated...
This $1,927,989 Project Grant award was issued by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research at the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to understand the molecular mechanisms and develop potential therapies for congenital aortic valve disease, a common and serious cardiovascular condition affecting approximately 2.5% of the U.S. population. The research...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $788,513 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to the University of California, San Diego (UCSD). The grant, titled "Mechanisms Underlying Maintenance of Cardiac Chamber Identity in Zebrafish," will support research to elucidate the genetic pathways that reinforce ventricular cardiomyocyte identity in the embryonic zebrafish heart. The project aims to identify the downstream...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA program 93.837 Cardiovascular Diseases Research is providing $807,948 to support a study on the genetics of left ventricular hypertrophy (LVH) and associated cardiac phenotypes. The primary awardee, The Medical College of Wisconsin, Inc. (MCW), will utilize whole genome sequencing data from the NHLBI TOPMed program to conduct association analyses and identify genetic variants related to LVH....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $751,980 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Oregon Health & Science University (OHSU) to investigate how cardiomyocyte growth is regulated in a fetal ovine model of reduced left ventricular filling. The goal is to understand how cardiomyocytes, the heart's muscle cells, grow and respond differently in fetuses with impaired left heart inflow, similar to the condition seen in Hypoplastic Left Heart...
This Project Grant award of $506,984 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the endocytic trafficking protein LRP1 in the cardiac neural crest cell lineage and its impact on congenital heart defects. The University of Pittsburgh, the prime awardee, will conduct a combination of in vivo and in vitro experiments using genetically modified mouse models to: Examine...
This $817,208 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the genetic basis and underlying biological mechanisms of heart failure. The primary awardee, The Broad Institute, Inc., will leverage high-throughput cell imaging and transcriptional profiling assays to systematically analyze the impact of genes associated with heart failure identified through genome-wide...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research into the Hippo-YAP signaling pathway and its role in cardiac regenerative repair. The $693,261 award, effective January 10, 2025 through December 31, 2028, aims to develop gene therapy strategies that can enhance cardiac function and promote regenerative responses following myocardial infarction. The research will...
This Project Grant award for $802,762.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research at The University of Texas Southwestern Medical Center to define the transcription factors and gene regulatory networks involved in human cardiac development, characterize genetic variants regulating cardiac gene programs, and assess the impact of coding and non-coding variants on molecular...